Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas

NACompletedINTERVENTIONAL
Enrollment

3,417

Participants

Timeline

Start Date

April 1, 2004

Primary Completion Date

December 31, 2015

Study Completion Date

May 31, 2017

Conditions
Primary Central Nervous System Neoplasms
Interventions
DRUG

vincristine, carboplatin

"vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21~carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21"

DRUG

vincristine, carboplatin, etoposide

"vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21~carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21~etoposide: 100 mg/m² i.v., week 1,4,7,10"

RADIATION

radiation therapy

"intracranial tumor site: 30 fractions, dose per fraction: 1.8 Gy, total dose: 54 Gy, duration 6 weeks~spinal tumor site: 28 fractions, dose per fraction: 1.8 Gy, total dose: 50.4 Gy duration 5 1/2 weeks"

Trial Locations (13)

1090

Allg. Krankenhaus der Stadt Wien Universitaets-Kinderklinik, Vienna

4200

Hospital San Joao, Porto

9100

Aalborg Hospital, Aalborg

10000

Children's Hospital Zagreb, Zagreb

35128

Azienda Ospedaliera di Padova, Padua

B-9000

Universitair Ziekenhuis Gent, Ghent

F-94805

Institut Gustave Roussy, Villejuif

DOH-86156

Klinikum Augsburg, Augsburg

N-9037

University of Tromso, Tromsø

04-736

Children's Memorial Health Institute, Warsaw

CH-8032

University Children's Hospital, Zurich

LS9 7TF

Leeds Cancer Centre at St. James's University Hospital, Leeds

NG7 2UH

Queen's Medical Centre, Nottingham

All Listed Sponsors
lead

Societe Internationale d'Oncologie Pediatrique

OTHER

NCT00276640 - Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas | Biotech Hunter | Biotech Hunter